6-溴吲哚-3-羧酸 | 101774-27-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-溴吲哚-3-羧酸
• 中文别名: 6-溴-1H-吲哚-3-甲酸；6-溴吲哚-3-甲酸；6-溴-3-吲哚甲酸
• 英文名称: 6-bromo-1H-indole-3-carboxylic acid
• 英文别名: 6-bromoindole-3-carboxylic acid；6-bromo-1H-indol-3-carboxylic acid
• CAS: 101774-27-0
• 化学式: C₉H₆BrNO₂
• 分子量: 240.056
• InChiKey: INNZWYJJSSRJET-UHFFFAOYSA-N

物化性质

• 熔点：
  212 °C
• 沸点：
  470.9±25.0 °C(Predicted)
• 密度：
  1.838±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-1h-indole-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-1h-indole-3-carboxylic acid
CAS number: 101774-27-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6BrNO2
Molecular weight: 240.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴吲哚-3-羧酸 在 1,1'-双(二苯基膦)二茂铁 、 palladium diacetate 、 sodium carbonate 、 Selectfluor 、 三乙胺 作用下， 以 水 、 二甲基亚砜 、 1,2-二氯乙烷 为溶剂， 反应 12.0h， 生成 methyl 3-fluoro-1H-indole-6-carboxylate
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
  [FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING

  摘要：

  本公开涉及抑制（例如，拮抗）干扰素基因激活因子（STING）的化学实体（例如，化合物或药用可接受的盐，和/或水合物，和/或共晶，和/或化合物的药物组合）。所述化学实体是有用的，例如，用于治疗在受试者（例如，人）中增加（例如，过量）STING激活（例如，STING信号传导）有助于病理和/或症状和/或进展的状况、疾病或失调（例如，癌症）。本公开还涉及含有相同成分的药物组合物以及使用和制备相同成分的方法。

  公开号：

  WO2020252240A1
• 作为产物：
  描述：

  6-溴吲哚 在 盐酸羟胺 、 sodium acetate 、 乙酸酐 、 sodium hydroxide 、 三氯氧磷 作用下， 以 溶剂黄146 为溶剂， 生成 6-溴吲哚-3-羧酸
  参考文献：
  名称：

  An investigation into the substituent effect of halogen atoms on the crystal structures of indole-3-carboxylic acid (ICA)

  摘要：

  本工作中对卤素原子（F，Cl，Br）取代吲哚-3-羧酸（ICA）的取代基效应对晶体结构进行了研究。通过晶体结构、分子间相互作用和π⋯π堆积模式，结合红外光谱、元素分析、核磁共振谱、差示扫描量热（DSC）、热重分析（TGA）和热台显微镜（HSM）测量进行了研究。结果表明，不同种类的卤素原子和不同取代位置对晶体结构、分子π⋯π堆积模式和分子间相互作用类型有显著影响。我们进一步将ICA的熔点与H–H、O–H和X–H（X = F，Cl，Br）相互作用相关联，并发现它们之间存在正相关关系。

  DOI：

  10.1039/c3ce40952j

文献信息

• Copper-Mediated Cascade C–H/N–H Annulation of Indolocarboxamides with Arynes: Construction of Tetracyclic Indoloquinoline Alkaloids
  作者：Ting-Yu Zhang、Chang Liu、Chao Chen、Jian-Xin Liu、Heng-Ye Xiang、Wei Jiang、Tong-Mei Ding、Shu-Yu Zhang

  DOI：10.1021/acs.orglett.7b03580

  日期：2018.1.5

  An efficient and environmentally benign Cu-mediated method was developed for direct cascade C–H/N–H annulation to construct polyheterocyclic indoloquinoline scaffolds. This method highlights an emerging strategy for transforming inert C–H bonds into versatile functional groups in organic synthesis and provides a new versatile approach for the efficient synthesis of indolo[3,2-c] and [2,3-c]quinoline

  开发了一种高效且环境友好的铜介导的方法，用于直接级联C–H / N–H环化，以构建多杂环吲哚并喹啉支架。该方法突出了在有机合成中将惰性C–H键转变为通用官能团的新兴策略，并为有效合成吲哚[3,2- c ]和[2,3- c ]喹啉生物碱提供了新的通用方法。
• [EN] COMPOUNDS AND METHODS FOR MODULATING FXR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR MODULER LE FXR
  申请人：LILLY CO ELI

  公开号：WO2009012125A1

  公开（公告）日：2009-01-22

  Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

  公式(I)的化合物：其中变量如本文所述定义，其药物组合物及其用途被披露为用于治疗血脂异常以及与血脂异常相关的疾病。
• [EN] INHIBITORS OF HEXOKINASE AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'HEXOKINASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：VTV THERAPEUTICS LLC

  公开号：WO2016196890A1

  公开（公告）日：2016-12-08

  Provided herein are substituted fused oxazoline derivatives and substituted pyran derivatives useful as inhibitors of the HKII enzyme. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention further provides medical uses of substituted fused oxazoline derivatives and substituted pyran derivatives, for example, as antitumor agents.

  提供本申请中的取代融合唑啉衍生物和取代吡喃衍生物，可用作HKII酶的抑制剂。本发明进一步提供了本发明化合物的药物组合物。本发明进一步提供了取代融合唑啉衍生物和取代吡喃衍生物的医疗用途，例如，作为抗肿瘤剂。
• [EN] HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS<br/>[FR] MODULATEURS DU RÉCEPTEUR HORMONAL POUR LE TRAITEMENT D'ÉTATS ET DE TROUBLES MÉTABOLIQUES
  申请人：ARDELYX INC

  公开号：WO2018039386A1

  公开（公告）日：2018-03-01

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

  这项发明涉及FXR的激活剂，可用于治疗自身免疫性疾病、肝病、肠道疾病、肾脏疾病、癌症以及FXR在其中发挥作用的其他疾病，其化学式为(I)：(I)，其中L1、A、X1、X2、R1、R2和R3如本文所述。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。